SCHEMBL6957228

SCHEMBL6957228

Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.70
PTGS2 P35354 1/20 0.70
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 3/20 0.53
TSHR P16473 2/20 0.53
CYP1A2 P05177 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
POLB P06746 3/20 0.45
CYP2C9 P11712 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CASP1 P29466 1/20 0.43
SRD5A2 P31213 1/20 0.43
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 2/20 0.40
RAB9A P51151 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6952147 0.85 ABCB11 (0.52) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
SCHEMBL10881659 0.84 ABCB11 (0.50) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
SCHEMBL10884756 0.84 ABCB11 (0.50) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
Zomepirac SCHEMBL25735 0.83 PTGS2 (1.00) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
SCHEMBL11486351 0.83 PTGS2 (0.67) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
Zomepirac SCHEMBL11495798 0.83 PTGS2 (1.00) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
Zomepirac SCHEMBL43061 0.82 PTGS2 (0.97) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
Zomepirac SCHEMBL9655800 0.82 PTGS2 (0.97) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
Zomepirac SCHEMBL28350948 0.82 PTGS2 (0.97) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR
SCHEMBL6953688 0.81 SMN1; SMN2 (0.51) ABCB11PTGS2SMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1154996-B1 AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN ORTHO MCNEIL PHARM INC (US) 2003-11-05 EP disclosed
US-6369228-B2 ANTICONVULSANTS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-04-09 US disclosed
US-20010044452-A1 Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain CARSON JOHN R (US) 2001-11-22 US disclosed
EP-1154996-A2 AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN Ortho-McNeil Pharmaceutical, Inc. (US) 2001-11-21 EP disclosed
US-6191142-B1 Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain ORTHO-MCNEIL PHARMACEUTICAL, INC. 2001-02-20 US disclosed
WO-2000048584-A2 AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-08-24 WO disclosed
US-5332736-A Anti-convulsant aroyl aminoacylpyrroles ORTHO PHARMACEUTICAL CORPORATION (US) 1994-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044452-A1 Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain OPRL1, AADAT, OPRK1 ABCB11 3932/4885PTGS2 440/4885SMN1; SMN2 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.